AUY922 Plus Trastuzumab Is Well Tolerated and Active in HER2-Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Oncotarget
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 1B/2 Study of the HSP90 Inhibitor AUY922 Plus Trastuzumab in Metastatic HER2-Positive Breast Cancer Patients who Have Progressed on Trastuzumab-Based Regimen
Oncotarget 2016 Jun 21;7(25)37680-37692, A Kong, D Rea, S Ahmed, JT Beck, R López López, L Biganzoli, AC Armstrong, M Aglietta, E Alba, M Campone, SF Hsu Schmitz, C Lefebvre, M Akimov, SC LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.